A Bold and Transformative Approach.
Our Vision
Improve the lives of people with immune-mediated diseases through innovative precision medicine.
Our Mission
Develop transformational precision therapies for immune-mediated diseases by leveraging cutting-edge biology, multi-modal data, and advanced analytics.
Leadership Team
Mark C. McKenna
Founder, Chairman & CEO
Mark C. McKenna
Olivier Laurent, Ph.D.
Chief Scientific Officer
Olivier Laurent, Ph.D.
Olivier Laurent, Ph.D. is our Chief Scientific Officer. Dr. Laurent is a seasoned biotech-pharma R&D leader with deep experience in drug development and bioinformatics. Dr. Laurent served as Chief Scientific Officer and Head of R&D at Prometheus Biosciences, until the company’s sale to Merck in June 2023. Previously, Dr. Laurent was Chief Scientific Officer at Intrepida Bio, an immuno-oncology company focused on developing novel antibodies for the treatment of fibrotic solid tumors. Before that, he was Chief Scientific Officer at Dauntless Pharmaceuticals, a clinical-stage company developing products in the metabolic and oncology therapeutic areas. Dr. Laurent has 25 years of experience in scientific roles of increasing responsibility, including at Sanofi, Bayer Biotech, Genentech, and Pfizer. While at Pfizer, he was Director of Protein Science and Target Identification and built the company’s peptide bioinformatics group. Dr. Laurent holds a Ph.D. in Cell Biology from the University of Grenoble and is a graduate of the École Normale Supérieure de Lyon in France.
Allison Luo, M.D.
Chief Medical Officer
Allison Luo, M.D.
Allison Luo, M.D. is our Chief Medical Officer. Dr. Luo is an experienced biotech executive who has successfully led many clinical programs and most recently served as the CMO of Prometheus Biosciences from August 2018 through the company’s sale to Merck in 2023. Prior to that, she served as CMO at Oppilan Pharma and Escalier Pharma and as SVP of Clinical Development for Gastroenterology at Progenity Inc. Before that, Dr. Luo was VP of Clinical Development at Ophthotech Corp., now Iveric bio, Inc. From 2006 to 2014, Dr. Luo was an Executive Director at Bristol-Myers Squibb Company where she was responsible for inflammatory bowel disease and led the Phase 3 program for Orencia (abatacept) and the Phase 2 programs for eldelumab (anti-IP10 antibody) for ulcerative colitis and Crohn’s disease. Earlier in her career, Dr. Luo was a Medical Director at Abbott Laboratories, where she submitted the Japanese NDA for Humira in rheumatoid arthritis and developed the clinical trial protocols for Humira in ulcerative colitis. Dr. Luo holds a B.S. in Biochemistry and an M.D. from Northwestern University.
William Sandborn, M.D.
Chief Strategy Officer
William Sandborn, M.D.
William J. Sandborn, M.D. is our Chief Strategy Officer. Dr. Sandborn is a world-renown clinician, entrepreneur, executive and advisor in the biopharmaceuticals industry. He previously served the President and Chief Medical Officer of Ventyx Biosciences, Inc. Dr. Sandborn co-founded Santarus, Inc. in 1999 and Shoreline Biosciences, Inc. in 2020, and served as the CMO of Shoreline from 2021 through 2022. He served as a professor of medicine and chief of the division of Gastroenterology at University of California, San Diego – School of Medicine from January 2011 to April 2021. Prior to UCSD, Dr. Sandborn served as a Professor of Medicine and Vice Chair, Division of Gastroenterology and Hepatology, from March 1993 to December 2010. Dr. Sandborn completed medical school and an internal medicine residency at Loma Linda University in Loma Linda, California. Dr. Sandborn also completed a gastroenterology fellowship at the Mayo Clinic in Rochester, Minnesota. He has a BA degree in Chemistry from Southern College, in Collegedale, Tennessee. Dr. Sandborn has published over 956 peer reviewed articles including articles in the New England Journal of Medicine, Nature, Lancet, JAMA, Annals of Internal Medicine, and Gastroenterology. In 2019 he was awarded the Sherman Prize for his work in inflammatory bowel disease.
Tim Andrews
Chief Legal Officer
Tim Andrews
Tim Andrews is our Chief Legal Officer and Secretary. Mr. Andrews is a seasoned legal executive with extensive experience advising biotech and pharmaceutical companies through all stages of growth, including IPOs and high-profile M&A transactions. Tim served as the General Counsel and Secretary of Prometheus Biosciences from 2020 through the company’s IPO and acquisition by Merck in June 2023. Prior to Prometheus, Mr. Andrews served as General Counsel and Secretary for Sienna Biopharmaceuticals, Inc. (Nasdaq: SNNA), from 2016 to 2019, where he led the acquisition of a UK-based biotech company and the company‘s subsequent IPO. Tim served as Senior Corporate Counsel and Assistant Secretary at Allergan, Inc. from 2011 until the company’s $70.5bn acquisition by Actavis in 2015, during which time he was lead counsel on Allergan’s U.S. and international business development transactions. He was previously a corporate attorney at Latham & Watkins LLP and a Business Analyst at Deloitte Consulting. Mr. Andrews holds a B.A. in Political Economy from the University of California, Berkeley and a J.D. from Loyola Law School, Los Angeles.
Vika Brough
Chief Financial Officer
Vika Brough
Vika Brough is our Chief Financial Officer. Ms. Brough has over 20 years of experience in the biotechnology and life science sectors, having served as a senior financial executive of private and public companies. Ms. Brough served as Senior Vice President of Finance at Prometheus Biosciences, Inc. where she led all corporate finance and planning activities and played a lead role in the Company’s IPO and subsequent financings. Prior to Prometheus, Ms. Brough was Head of Finance at Human Longevity, Inc. Before joining industry, Ms. Brough was an auditor for Ernst & Young Assurance practice in San Diego where she served many multinational public and private clients in life science, medical devices, and technology industries. Ms. Brough graduated from San Diego State University with a Bachelor of Accounting degree. She is a Certified Public Accountant with the State of California (inactive).
Nori Ebersole
Chief People Officer
Nori Ebersole
Nori Ebersole is our Chief People Officer. Ms. Ebersole is a proven HR executive with a successful record of building high-performing teams at growth companies and achieving compelling results for companies and their people. Ms. Ebersole served as the Chief People Officer at Prometheus Biosciences from March 2021 through the company’s sale to Merck in 2023. Ms. Ebersole led the talent acquisition ramp up and, under her leadership, Prometheus Biosciences was recognized as a 2023 Fortune Best Workplaces in BioPharma. Prior to joining Prometheus Biosciences, Ms. Ebersole served as EVP & Chief Human Resources Officer for Urovant Sciences, Inc from 2017 to 2021, through Urovant’s IPO and subsequent take-private merger with Sumitomo Dainippon at a significant premium. Prior to Urovant, Nori was the Chief Human Resources Officer at Paul Hastings, LLP. Ms. Ebersole also served 18 years at Allergan Inc., through their sale to Actavis for $70.5bn. Ms. Ebersole earned a B.S. in Business Administration from the University of Southern California Marshall School of Business and actively participates in local charitable organizations such as Big Brothers Big Sisters of Orange County and others.
Jordan Zwick
Chief Business Officer
Jordan Zwick
Jordan Zwick is our Chief Business Officer. Mr. Zwick is an experienced leader in corporate strategy and business development in the biopharmaceutical sector. Mr. Zwick served as strategic advisor to Prometheus Biosciences prior to its sale to Merck in June 2023. Previously, Mr. Zwick served as SVP, Corporate Business Development and Investor Relations at Amarin Corp (AMRN), closing multiple transactions for global partnering of the lead asset. Jordan served as SVP, Chief Strategy Officer at InflaRx N.V. (IFRX), where he was responsible for leading corporate strategy, business & corporate development, investor relations and was instrumental in the public financings of the Company. Mr. Zwick has vast industry operational experience at companies such as Medtronic, Salix Pharmaceuticals and Bausch Health. As part of the team that sold Salix to Valeant Pharmaceuticals (now Bausch Health Companies) for $14.5 billion in 2015, Mr. Zwick eventually became head of strategy at the Salix business unit, responsible for leading all business development transactions, alliance management, strategic planning and portfolio management, playing a key role in the turnaround story of Bausch Health. He holds B.A., M.S. degrees from Florida Atlantic University and a M.B.A. from the University of San Francisco.
Board of Directors
Mark C. McKenna
Founder, Chairman & CEO
Paul Berns
Director
Paul Berns
Mr. Berns was a consultant to the pharmaceutical industry from July 2016 to August 2018, as well as from August 2012 to March 2014 and from July 2005 to March 2006. Prior to that, Mr. Berns was Vice President and General Manager of the Immunology, Oncology and Pain Therapeutics business unit of Abbott Laboratories from 2001 to 2002, and from 2000 to 2001, he served as Vice President, Marketing of BASF Pharmaceuticals/Knoll, when it was acquired by Abbott Laboratories in 2001. Earlier in his career, Mr. Berns held various positions, including senior management roles, at Bristol Myers Squibb (BMS) from 1990 to 2000.
Mr. Berns received his B.S. in Economics from the University of Wisconsin.
Kristina Burow
Director
Kristina Burrow
Ms. Burow is a co-founder and director of Neumora Therapeutics, Orbital Therapeutics and is a director of Beam Therapeutics (BEAM), Gossamer Bio (GOSS), Scholar Rock (SRRK), Boundless Bio, Autobahn Therapeutics, ROME Therapeutics, Pretzel Therapeutics, Metsera Therapeutics and Treeline Biosciences, among others. She previously was a co-founder and Director of Receptos (RCPT – acquired by Celgene for $7.2 billion), and a director at Vir Biotechnology (VIR) and Vividion Therapeutics (acquired by Bayer AG), among others. Ms. Burow has participated and led investments in a number of other ARCH portfolio companies including Interline Therapeutics, Erasca (ERAS), Dewpoint Therapeutics, Aledade, Kura Oncology (KURA), Kythera Biopharmaceuticals (KYTH – acquired by Allergan), and Ikaria (acquired by Mallinckrodt).
Prior to joining ARCH, Ms. Burow was an Associate with the Novartis BioVenture Fund in San Diego. As an early employee at the Genomics Institute of the Novartis Research Foundation (GNF), she directed Chemistry Operations and was active in Business Development where she helped create numerous companies as spinouts from GNF.
Ms. Burow holds an M.B.A. from the University of Chicago, an M.A. in Chemistry from Columbia University and a B.S. in Chemistry from the University of California, Berkeley.
David Bonita, M.D.
Director
David Bonita, M.D.
David Bonita is a General Partner of OrbiMed and has been with OrbiMed since 2004. Prior to joining OrbiMed, David worked as a corporate finance analyst in the healthcare investment banking groups of Morgan Stanley and UBS. He has also published scientific articles in peer-reviewed journals based on signal transduction research performed at the Harvard Medical School. David received his A.B. degree magna cum laude in Biological Sciences from Harvard University and his joint M.D./M.B.A. from Columbia University where he was elected to the Alpha Omega Alpha Medical Honor Society and Beta Gamma Sigma Business Honor Society.
Joseph C. Papa
Director
Joseph C. Papa
Joseph C. Papa brings over 35 years of experience in the healthcare and pharmaceutical industry. Mr. Papa was named Chief Executive Officer at Emergent BioSolutions in February 2024. Mr Papa recently served as chief executive officer and chairman at Bausch and Lomb Corporation, a global eye health company. Prior to his role at Bausch and Lomb, he was the chief executive officer and chairman of Bausch Health, now Bausch Health Companies Inc. He also served as chairman and CEO of Perrigo, and held leadership positions at Cardinal Health, Watson Pharmaceuticals, and Novartis. He currently is the chairman of the board of SparingVision, a privately held genomic medicines company, and is a member of the board of directors of Candel Therapeutics. He also served as a member of the board of directors of Prometheus Biosciences (acquired by Merck in 2023).
Scott Glenn
Director
Scott Glenn
Scott Glenn is Managing Partner of Windamere Venture Partners and Chairman of ReBalance Health. He founded and sold, or took public, numerous biotech companies, including Prometheus Laboratories, Santarus, DexCom, Conception Technologies, NovaCardia, Cadence Pharmaceuticals, SkinMedica, VelosBio, Alastin Skincare and most recently Prometheus Biosciences.
Advisors
Richard Graham, Ph.D.
Scientific Advisor
Richard Graham, Ph.D.
Richard A. Graham, recently served as Senior Vice President, Development of Theravance Biopharma until February 2024, where he was responsible for leading the progression of late-stage clinical assets through regulatory filing and approval. Since joining Theravance Biopharma, Dr. Graham served as Vice President of Clinical Pharmacology, and more recently, as Vice President of Clinical Development.
Prior to joining Theravance Biopharma, Dr. Graham spent five years at GlaxoSmithKline working in the area of Drug Metabolism and Pharmacokinetics, seven years at Genentech/Roche as a clinical pharmacologist and Global Development Team Leader, and one year at Onyx Pharmaceuticals where he headed Translational Medicine. In his nearly 20-year career, he worked across all stages of drug development and all major therapeutic areas.
Dr. Graham received his Bachelor’s and Master’s degree in Biochemistry from Iowa State University and his Doctorate of Philosophy degree in Pharmaceutical Sciences from The University of North Carolina at Chapel Hill.
Investors
